FIELD: biotechnology.
SUBSTANCE: invention relates to a vaccine composition for a malignant tumor overexpressing WT1, for mucosal introduction for use in inducing cellular immunity. Said composition contains: a therapeutically effective amount of Db126 peptide and a therapeutically effective amount of a first activator of cell immunity induction, which is TLR7 ligand selected from TLR7-II and resiquimod.
EFFECT: invention enables efficient induction of cell-mediated immunity against cancer.
6 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER VACCINE COMPOSITION CONTAINING PEPTIDE WT1 FOR TRANSDERMAL ADMINISTRATION | 2014 |
|
RU2685933C2 |
| ANTICANCER VACCINE COMPOSITION CONTAINING WT1 PEPTIDE FOR TRANSDERMAL ADMINISTRATION | 2014 |
|
RU2687144C2 |
| ANTI-CANCER VACCINE PREPARATION CONTAINING PEPTIDE WT1 IN THE FORM OF A TRANSDERMAL INTRODUCTION TAPE | 2014 |
|
RU2697443C2 |
| VACCINE BASED ON B-CELLS, LOADED WITH LIGANDS OF T-CELLS-NATURAL KILLERS AND ANTIGEN | 2006 |
|
RU2420311C2 |
| ANTIGEN-SPECIFIC HELPER T-CELL RECEPTOR GENES | 2013 |
|
RU2680588C2 |
| TOLL-LIKE RECEPTOR 7 OR 8 AGONIST AND CHOLESTEROL COMPLEX AND ITS USE | 2020 |
|
RU2790702C1 |
| MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
| METHOD FOR ACTIVATING CYTOTOXIC T-LYMPHOCYTES IN A POPULATION OF BLOOD MONONUCLEAR CELLS USING MEMBRANE VESICLES OBTAINED FROM GENETICALLY MODIFIED TUMOR CELLS OF M14 MELANOMA WITH OVEREXPRESSION OF INTERLEUKIN 2 | 2022 |
|
RU2790867C1 |
| VACCINATIVE TUMOR VACCINE COMPOSITION | 2008 |
|
RU2682726C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
